ClinicalTrials.gg
RecruitingNCT06416956Baby-CINOUpdated May 16, 2024

Baby-CINO: CaffeINe Treatment Optimisation in Premature Infants

An observational study in Infant,Premature and Caffeine, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to participants aged Up to 37 Weeks. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by University of Oxford · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
Up to 37 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Premature Birth by University of Oxford — 3 open to participants now, 4 under way, none of them phase 3. Premature Birth · University of Oxford.

Started
2023
with 1 other
Observational
9 of 11
3 open now
Registered
10th of 11
by date

Among the 11 studies in Premature Birth by University of Oxford, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 10th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

3 of the 11 studies in Premature Birth by University of Oxford are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: Up to 37 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Premature Birth by University of Oxford, or all of them as a file.
02

Study summary

This study investigates how brain activity and breathing changes in premature babies when their dose of caffeine treatment is changed or stopped. The study will assess premature babies receiving caffeine treatment as part of their clinical care. Brain activity will be recorded just before caffeine dose is changed and again two days afterwards. Breathing and other 'vital signs' (breathing rate, heart rate, oxygen saturation) will be recorded from the baby's monitor between the recordings of brain activity and for up to two weeks afterwards.

03

Conditions studied

  • Infant,Premature
  • Caffeine

Browse trials for

04

Who can participate

Ages eligible
Up to 37 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All participants will be inpatients on the Newborn Care Unit and born prematurely (before 37 weeks gestation)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born to a mother aged 16 or over
  • Admitted to the Newborn Care Unit, John Radcliffe Hospital
  • Born prematurely (before 37 weeks' gestation)
  • Parent given informed written consent
  • Receiving caffeine citrate

Exclusion criteria

Exclusion Criteria:

  • Known chromosomal abnormality or life-threatening congenital abnormality
  • Severe hypoxic insult at birth
  • Intraventricular haemorrhage grade III or IV or other severe neurological pathology
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Preterm infant

    Preterm infants receiving caffeine (prescribed clinically) will be studied

    Drug: Caffeine

Interventions

  • We will record infant\'s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.

06

What researchers measure

Primary outcomes

  1. Respiration

    Change in respiratory dynamics between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later

    Time frame: From baseline to two days later

  2. Brain activity

    Change in EEG activity between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later

    Time frame: From baseline to two days later

Secondary outcomes

  1. Heart rate

    Change in heart rate between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later

    Time frame: From baseline to two days later

  2. Oxygen saturation

    Change in oxygen saturation between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later

    Time frame: From baseline to two days later

07

Study locations

1 of 1 sites recruiting
  • Newborn Care Unit, John Radcliffe Hospital
    Oxford, Oxfordshire OX3 9DU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Sep 2024, 8 months after the start.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 8 months is below that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
May 16, 2024
StartActual
Dec 11, 2023
Primary completionEst.
Sep 1, 2024
CompletionEst.
Sep 1, 2024
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06416956
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Dec 11, 2023
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
May 16, 2024

Study contacts

Caroline Hartley
Contact
caroline.hartley@paediatrics.ox.ac.uk
+44 1865 234537
Caroline Hartley
principal investigator · University of Oxford

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion